Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
N-acetylcysteine for Restricted and Repetitive Behaviors in Children With Autism
NCT05664789Phase 3Recruiting
- Sponsor
- Stanford University
- Start
- Apr 2023
- Primary completion
- Jan 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Autism Spectrum Disorder (ASD) comparing N-acetylcysteine with Placebo (2 arms). Primary endpoints: Children's Yale Brown-Obsessive Compulsive Scale for Autism Spectrum Disorder at 12 weeks and Glutamatergic neurometabolites at 12 weeks. Started Apr 2023; status: recruiting.
02
Drugs
acetylcysteine
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT05664789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05664789.